Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J N Hagstrom

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|August 15, 2002
Gene therapy for hereditary hematological disordersR W Herzog, J N Hagstrom
Proceedings of the National Academy of Sciences of the United States of America|April 2, 1996
Successful expression of human factor IX following repeat administration of adenoviral vector in miceJ Walter, Q You, J N Hagstrom, et al.
Thrombosis and Haemostasis|December 1, 1995
The pharmacokinetics and lipoprotein fraction distribution of intramuscular vs. oral vitamin K1 supplementation in women of childbearing age: effects on hemostasisJ N Hagstrom, E G Bovill, R F Soll, et al.
The Journal of Pediatrics|December 8, 1998
Prevalence of the factor V leiden mutation in children and neonates with thromboembolic diseaseJ N Hagstrom, J Walter, R Bluebond-Langner, et al.
Blood|February 3, 1998
Human factor IX corrects the bleeding diathesis of mice with hemophilia BS H Kung, J N Hagstrom, D Cass, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 1997
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virusR W Herzog, J N Hagstrom, S H Kung, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2001
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9P A Fields, V R Arruda, E Armstrong, et al.
Gene Therapy|April 21, 2001
Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 miceP A Fields, E Armstrong, J N Hagstrom, et al.
Blood|February 7, 2001
Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoterJ N Hagstrom, L B Couto, C Scallan, et al.
Journal of the American College of Cardiology|April 1, 1993
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectorisH K Gold, F W Torres, H D Garabedian, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|August 15, 2002
Gene therapy for hereditary hematological disordersR W Herzog, J N Hagstrom
Proceedings of the National Academy of Sciences of the United States of America|April 2, 1996
Successful expression of human factor IX following repeat administration of adenoviral vector in miceJ Walter, Q You, J N Hagstrom, et al.
Thrombosis and Haemostasis|December 1, 1995
The pharmacokinetics and lipoprotein fraction distribution of intramuscular vs. oral vitamin K1 supplementation in women of childbearing age: effects on hemostasisJ N Hagstrom, E G Bovill, R F Soll, et al.
The Journal of Pediatrics|December 8, 1998
Prevalence of the factor V leiden mutation in children and neonates with thromboembolic diseaseJ N Hagstrom, J Walter, R Bluebond-Langner, et al.
Blood|February 3, 1998
Human factor IX corrects the bleeding diathesis of mice with hemophilia BS H Kung, J N Hagstrom, D Cass, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 1997
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virusR W Herzog, J N Hagstrom, S H Kung, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2001
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9P A Fields, V R Arruda, E Armstrong, et al.
Gene Therapy|April 21, 2001
Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 miceP A Fields, E Armstrong, J N Hagstrom, et al.
Blood|February 7, 2001
Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoterJ N Hagstrom, L B Couto, C Scallan, et al.
Journal of the American College of Cardiology|April 1, 1993
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectorisH K Gold, F W Torres, H D Garabedian, et al.
Pageof 2